Co-occurrence of ESR1 mutations with other alterations

Along with the Oncology Brothers, Paolo Tarantino, MD, explores how ESR1 mutations frequently co-occur with other molecular alterations and the importance of maximizing endocrine-based therapy before moving on to antibody-drug conjugates or chemotherapy.

EP: 1.Overview of phase 3 EMERALD study of elacestrant for ER+, HER2- MBC

EP: 2.Episode 2: Incidence of ESR1 mutations and best practices for testing

Now Viewing

EP: 3.Co-occurrence of ESR1 mutations with other alterations

EP: 4.Elacestrant as second-line therapy for ESR1-mutated, endocrine-sensitive disease

EP: 5.EMERALD subgroup analysis: Elacestrant in endocrine-sensitive disease

EP: 6.Elacestrant: Clinical Pearls for Adverse Effect Management

EP: 7.Emerging data on oral selective estrogen receptor degraders

Bardia A, Cortés J, Bidard FC, et al. Elacestrant in ER+, HER2- metastatic breast cancer with ESR1-mutated tumors: subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups. Clin Cancer Res. 2024;30:4299-4309. https://doi.org/10.1158/1078-0432.CCR-24-1073.

Recent Videos